ANAPHYLACTIC REACTIONS TO DIAZIQUONE

  • 1 January 1984
    • journal article
    • research article
    • Vol. 68  (10) , 1215-1217
Abstract
Diaziquone, an aziridinylbenzoquinone currently in phase II-III trials, is an alkylating agent, the major toxic effect of which is myelosuppression. Six cases [human] were reported of hypersensitivity attributable to diaziqunone. In 5 patients an acute reaction characterized by hypotension, bronchospasm and urticaria was observed. In 1 patient a delayed urticarial rash was noted. Resolution was rapid in all patients but 1, who responded to standard treatment over a period of hours. No reaction was fatal. Approximately 2000 patients have been treated with diaziquone in clinical trials sponsored by the National Cancer Institute. It is suggested that the reaction may not be to the drug itself but to the vehicle (dimethylacetamide) in which diaziquone is formulated. Studies to elucidate the relative contribution of drug and vehicle are warranted.

This publication has 2 references indexed in Scilit: